Breaking News

Octagon Advances Quantum Platform, Expands Internationally

Octagon adds Content Manager and Document Publisher to Submission Manager as the next applications for its Quantum platform.

By:

Octagon Research Solutions, Inc. has added Content Manager and Document Publisher to Submission Manager as the next applications for its Quantum platform. The Quantum platform consolidates key regulatory information capabilities in a consolidated system that provides robust, highly scalable, and top-tier capabilities to life science companies of all sizes, according to the company.

Combined with the Quantum platform’s Submission Manager, clients can now develop and publish content from a single pre-configured system. The two new business applications are components of Octagon’s cloud strategy. “The multi-tenant architecture of the Quantum platform provides a strong foundation for our cloud strategy,” said Kirk Gallion, president, Octagon Research Solutions, Inc. “Our innovative business applications layered on the Quantum platform offer a compelling cloud-based solution, while still providing the option for a traditional on-premise installation. These business applications extend the value of the platform and connect the dots between the document and submission lifecycle.”

Octagon is also expanding globally, adding 100 clinical and regulatory professionals, expanding its U.S. headquarters location, and broadening its presence in Europe and in the Asia-Pacific region with new facilities in the UK and in India.

“Octagon’s global expansion demonstrates our ongoing commitment to supporting our valued clients with region-specific regulatory experts and to expanding our business in new regions around the world,” said James C. Walker, chairman and chief executive officer, and Octagon Research Solutions. “With our client portfolio growing more than 20% just this year and growth projections well beyond that for 2012, Octagon’s global expansion supports the robust demand for our clinical and regulatory software solutions and services.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters